1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy

 
• By Neena Brizmohun

Bluebird Bio and Celgene have secured a place on both the EMA’s PRIME scheme and the US FDA’s breakthrough therapy designation program for their multiple myeloma CAR-T therapy, bb2121. Meanwhile, Bluebird talks about how “incredibly helpful” PRIME has been with the development of LentiGlobin for beta-thalassemia.

T-cells attacking cancer_1200x675
Bluebird and Celgene's CAR-T therapy makes it on two key regulatory schemes

Bluebird Bio and Celgene Corporation have succeeded in getting the chimeric antigen receptor T cell (CAR T-cell) therapy they are developing for use in previously treated multiple myeloma patients onto two key regulatory schemes that promise to accelerate the product’s development in the EU and the US.

bb2121 was this month accepted onto the European Medicines Agency’s priority medicines (PRIME) scheme for getting drugs for unmet medical needs to patients faster

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.